Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Lexaria Bioscience Corp. (NASDAQ:LEXX) has contracted a research organization to conduct the first-ever fluorescently tagged DehydraTECH-semaglutide (FTS) rodent biodistribution study. The study will compare two formulations: one mimicking Rybelsus® and another using Lexaria's DehydraTECH processing. The research aims to track how semaglutide distributes in the body using fluorescent imaging in Sprague-Dawley rats, examining tissues including brain, pancreas, lung, kidney, liver, and heart. The study will also evaluate GLP-1 receptor binding patterns using immunofluorescence methodology. Results are expected in May 2025.
Lexaria Bioscience Corp. (NASDAQ:LEXX) ha commissionato a un'organizzazione di ricerca lo svolgimento del primo studio di biodistribuzione su roditori con DehydraTECH-semaglutide (FTS) etichettato fluorescentemente. Lo studio confronterà due formulazioni: una che imita Rybelsus® e un'altra che utilizza il processo DehydraTECH di Lexaria. La ricerca mira a seguire la distribuzione della semaglutide nel corpo utilizzando l'imaging fluorescente in ratti Sprague-Dawley, esaminando tessuti come cervello, pancreas, polmoni, reni, fegato e cuore. Lo studio valuterà anche i modelli di legame dei recettori GLP-1 utilizzando una metodologia di immunofluorescenza. I risultati sono attesi per maggio 2025.
Lexaria Bioscience Corp. (NASDAQ:LEXX) ha contratado a una organización de investigación para llevar a cabo el primer estudio de biodistribución en roedores con DehydraTECH-semaglutide (FTS) etiquetado fluorescente. El estudio comparará dos formulaciones: una que imita Rybelsus® y otra que utiliza el procesamiento DehydraTECH de Lexaria. La investigación tiene como objetivo rastrear cómo se distribuye la semaglutida en el cuerpo mediante imágenes fluorescentes en ratas Sprague-Dawley, examinando tejidos que incluyen cerebro, páncreas, pulmones, riñones, hígado y corazón. El estudio también evaluará los patrones de unión del receptor GLP-1 utilizando la metodología de inmunofluorescencia. Se esperan resultados para mayo de 2025.
렉사리아 바이오사이언스 주식회사(NASDAQ:LEXX)가 첫 번째 형광표지된 DehydraTECH-semaglutide(FTS) 설치류 바이오 분포 연구를 수행하기 위해 연구 기관에 계약했습니다. 이 연구는 Rybelsus®를 모방한 제형과 Lexaria의 DehydraTECH 가공을 사용한 제형 두 가지를 비교합니다. 이 연구의 목표는 세마글루타이드가 체내에서 어떻게 분포되는지를 추적하는 것입니다 스프라그-도울리 쥐에서 형광 이미징을 사용하여 뇌, 췌장, 폐, 신장, 간 및 심장 등 조직을 조사합니다. 연구는 면역형광 방법론을 사용하여 GLP-1 수용체 결합 패턴도 평가할 것입니다. 결과는 2025년 5월에 나올 것으로 예상됩니다.
Lexaria Bioscience Corp. (NASDAQ:LEXX) a confié à une organisation de recherche la réalisation de la première étude de biodistribution sur des rongeurs avec DehydraTECH-semaglutide (FTS) marqué fluorescent. L'étude comparera deux formulations : l'une imitant Rybelsus® et l'autre utilisant le traitement DehydraTECH de Lexaria. La recherche vise à suivre comment la semaglutide se distribue dans le corps en utilisant l'imagerie fluorescente chez les rats Sprague-Dawley, examinant des tissus tels que le cerveau, le pancréas, les poumons, les reins, le foie et le cœur. L'étude évaluera également les schémas de liaison du récepteur GLP-1 à l'aide de la méthodologie d'immunofluorescence. Les résultats sont attendus pour mai 2025.
Die Lexaria Bioscience Corp. (NASDAQ:LEXX) hat eine Forschungsorganisation beauftragt, um die erste jemals durchgeführte biodistribution mit fluoreszenzmarkiertem DehydraTECH-semaglutide (FTS) an Nagetieren durchzuführen. Die Studie wird zwei Formulierungen vergleichen: eine, die Rybelsus® imitiert, und eine andere, die den DehydraTECH-Prozess von Lexaria verwendet. Die Forschung zielt darauf ab, nachzuvollziehen, wie Semaglutid im Körper verteilt wird mithilfe von fluoreszierender Bildgebung bei Sprague-Dawley-Ratten, wobei Gewebe wie Gehirn, Bauchspeicheldrüse, Lunge, Niere, Leber und Herz untersucht werden. Die Studie wird auch die Bindungsmuster des GLP-1-Rezeptors mithilfe von Immunfluoreszenzmethoden bewerten. Die Ergebnisse werden im Mai 2025 erwartet.
- First-ever study to track DehydraTECH-GLP-1 biodistribution, potentially providing competitive advantages
- Direct comparison with Rybelsus® formulation could demonstrate DehydraTECH's potential benefits
- Study results could facilitate future industry partnerships
- Study results won't be available until May 2025, indicating a long wait for potential commercialization
- No guarantee of positive study outcomes or superior performance versus existing formulations
Insights
This preclinical biodistribution study marks a significant milestone in Lexaria's development of DehydraTECH-enhanced GLP-1 delivery. The study's design, comparing DehydraTECH-processed semaglutide against a Rybelsus-mimicking formulation, could provide important insights into potential advantages in drug distribution and receptor binding. The use of fluorescent imaging and GLP-1 receptor antibodies will offer detailed visualization of tissue localization patterns.
The study's outcomes could be particularly relevant given the
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules
KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / November 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has engaged a contract research organization to perform the world's first-ever fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study (the "Study").
Distribution of a drug once it enters the body can provide vital clues as to the understanding of that drug's ability to bind with targeted receptor cells, avoid concentration at physical sites that might be prone to fostering adverse side effects, and increase the drug's ultimate efficacy. Lexaria hopes to discover whether the DehydraTECH processing of semaglutide improves its biodistribution in any significant way compared to conventional orally administered semaglutide formulation practices.
The FTS will be tracked via fluorescent imaging detection to evidence how and where the semaglutide distributes and localizes following oral ingestion in Sprague-Dawley rats. Later in the Study, the animals will be euthanized and various key tissues will be examined including the brain, pancreas, lung, kidney, liver and heart for more detailed fluorescent imaging detection showing very specific tissue localization patterns and concentrations.
Lexaria has already begun the early-stage collaboration with the third-party laboratory that will synthesize the FTS that will then be used to create the DehydraTECH-semaglutide test articles. There will be two different test articles manufactured and tested:
FTS will be combined with ingredients in the proportions used within the Rybelsus® orally-administered product sold today designed to mimic Rybelsus® performance, without DehydraTECH processing.
FTS will be combined with patented DehydraTECH ingredients and processes to evidence potential biodistribution differences when DehydraTECH is used compared to the Rybelsus®-mimicking control FTS formulation.
The Study will also include use of certain glucagon-like peptide-1 ("GLP-1") receptor specific antibodies detectable through an immunofluorescence methodology to allow the analytical laboratory to confirm the extent of GLP-1 receptor binding of the two FTS formulations in the tissue samples taken from the animals, providing an additional detailed measure of the FTS distribution and localization patterns.
Results from the Study will enhance any future communications between Lexaria and prospective industry partners. Study work has already begun with completion and final reporting expected in May, 2025.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on accesswire.com
FAQ
What is the purpose of Lexaria's DehydraTECH-semaglutide biodistribution study?
When will Lexaria (LEXX) complete its DehydraTECH-semaglutide study?
How will Lexaria (LEXX) compare DehydraTECH-semaglutide to Rybelsus?
